Richards, Merrill & Peterson’s Zymeworks ZYME Stock Holding History

Richards, Merrill & Peterson’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$293	–	533
2024 Q4	$293	Buy	+20	New	+$280	﹤0.01%	481

Other funds holding ZYME

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Richards, Merrill & Peterson's ZYME Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Zymeworks (ZYME) in Q1 2025, closing a stake of 20 shares — an estimated $293 sold.

Richards, Merrill & Peterson first reported a position in ZYME in Q4 2024 and held it in 1 quarter. The position peaked at $293 in Q4 2024. 184 funds tracked by Wall St. Rank hold ZYME as of Q1 2025.

Richards, Merrill & Peterson reported no remaining Zymeworks position as of Q1 2025 after selling out during the quarter.
Richards, Merrill & Peterson sold 20 Zymeworks shares in Q1 2025, an estimated $293.
Richards, Merrill & Peterson first reported a position in Zymeworks in Q4 2024 and held it in 1 quarter.
Richards, Merrill & Peterson's Zymeworks position peaked at $293 in Q4 2024.
184 funds tracked by Wall St. Rank held Zymeworks as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.